Comprehensive Stock Comparison
Compare BridgeBio Oncology Therapeutics Inc. (BBOT) vs Apple Inc. (AAPL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Value | BBOT | Lower P/E (21.8x vs 31.1x) |
| Stability / Safety | BBOT | Beta 0.26 vs AAPL's 1.28 |
| Dividends | AAPL | 0.4% yield; 14-year raise streak; BBOT pays no meaningful dividend |
| Momentum (1Y) | AAPL | +9.7% vs BBOT's -9.2% |
| Efficiency (ROA) | AAPL | 31.1% ROA vs BBOT's -23.7%, ROIC 64.5% vs -64.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing precision cancer drugs targeting specific genetic mutations in tumors. It generates revenue primarily through research collaborations and licensing deals — with future income dependent on successful drug development and commercialization — though currently in pre-revenue stage as it advances its clinical pipeline. The company's competitive advantage lies in its specialized focus on difficult-to-target oncogenes like KRAS and PI3Kα, leveraging BridgeBio Pharma's broader platform for drug discovery and development.
Apple is a technology giant that designs and sells premium consumer electronics — most famously the iPhone — along with related software and services. It generates revenue primarily from hardware sales (roughly 80% of total) and a fast-growing services segment (around 20%) that includes the App Store, subscriptions, and licensing. Its key competitive advantage is a powerful ecosystem that locks users into its hardware, software, and services through seamless integration and high switching costs.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AAPL leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). BBOT leads in 1 (Valuation Metrics). 1 tied.
Financial Metrics (TTM)
AAPL and BBOT operate at a comparable scale, with $435.6B and $0 in trailing revenue.
| Metric | BBOTBridgeBio Oncolog… | AAPLApple Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $435.6B |
| EBITDAEarnings before interest/tax | -$124M | $152.9B |
| Net IncomeAfter-tax profit | -$115M | $117.8B |
| Free Cash FlowCash after capex | -$96M | $123.3B |
| Gross MarginGross profit ÷ Revenue | — | +47.3% |
| Operating MarginEBIT ÷ Revenue | — | +32.4% |
| Net MarginNet income ÷ Revenue | — | +27.0% |
| FCF MarginFCF ÷ Revenue | — | +28.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +15.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -20.0% | +18.3% |
Valuation Metrics
At 21.8x trailing earnings, BBOT trades at a 38% valuation discount to AAPL's 35.4x P/E.
| Metric | BBOTBridgeBio Oncolog… | AAPLApple Inc. |
|---|---|---|
| Market CapShares × price | $794M | $3.88T |
| Enterprise ValueMkt cap + debt − cash | $793M | $3.97T |
| Trailing P/EPrice ÷ TTM EPS | 21.80x | 35.41x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 31.15x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.98x |
| EV / EBITDAEnterprise value multiple | — | 27.45x |
| Price / SalesMarket cap ÷ Revenue | — | 9.33x |
| Price / BookPrice ÷ Book value/share | 0.88x | 53.76x |
| Price / FCFMarket cap ÷ FCF | — | 39.33x |
Profitability & Efficiency
AAPL delivers a 133.5% return on equity — every $100 of shareholder capital generates $134 in annual profit, vs $-26 for BBOT. On the Piotroski fundamental quality scale (0–9), AAPL scores 7/9 vs BBOT's 4/9, reflecting strong financial health.
| Metric | BBOTBridgeBio Oncolog… | AAPLApple Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -25.7% | +133.5% |
| ROA (TTM)Return on assets | -23.7% | +31.1% |
| ROICReturn on invested capital | -64.9% | +64.5% |
| ROCEReturn on capital employed | -83.3% | +69.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | — | 1.67x |
| Net DebtTotal debt minus cash | -$2M | $89.7B |
| Cash & Equiv.Liquid assets | $2M | $33.5B |
| Total DebtShort + long-term debt | $0 | $123.3B |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in AAPL five years ago would be worth $21,049 today (with dividends reinvested), compared to $9,843 for BBOT. Over the past 12 months, AAPL leads with a +9.7% total return vs BBOT's -9.2%. The 3-year compound annual growth rate (CAGR) favors AAPL at 21.9% vs BBOT's -0.5% — a key indicator of consistent wealth creation.
| Metric | BBOTBridgeBio Oncolog… | AAPLApple Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -18.4% | -2.4% |
| 1-Year ReturnPast 12 months | -9.2% | +9.7% |
| 3-Year ReturnCumulative with dividends | -1.6% | +81.2% |
| 5-Year ReturnCumulative with dividends | -1.6% | +110.5% |
| 10-Year ReturnCumulative with dividends | -1.6% | +1027.4% |
| CAGR (3Y)Annualised 3-year return | -0.5% | +21.9% |
Risk & Volatility
BBOT is the less volatile stock with a 0.26 beta — it tends to amplify market swings less than AAPL's 1.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AAPL currently trades 91.5% from its 52-week high vs BBOT's 67.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BBOTBridgeBio Oncolog… | AAPLApple Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.26x | 1.28x |
| 52-Week HighHighest price in past year | $14.87 | $288.61 |
| 52-Week LowLowest price in past year | $8.50 | $169.21 |
| % of 52W HighCurrent price vs 52-week peak | +67.5% | +91.5% |
| RSI (14)Momentum oscillator 0–100 | 40.7 | 57.5 |
| Avg Volume (50D)Average daily shares traded | 267K | 40.9M |
Analyst Outlook
Wall Street rates BBOT as "Buy" and AAPL as "Buy". Consensus price targets imply 132.6% upside for BBOT (target: $23) vs 14.7% for AAPL (target: $303). AAPL is the only dividend payer here at 0.39% yield — a key consideration for income-focused portfolios.
| Metric | BBOTBridgeBio Oncolog… | AAPLApple Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $23.33 | $303.11 |
| # AnalystsCovering analysts | 2 | 109 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 14 |
| Dividend / ShareAnnual DPS | — | $1.03 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 24 | Feb 26 | Change |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | 100 | 118.06 | +18.1% |
| Apple Inc. (AAPL) | 100 | 150.29 | +50.3% |
Apple Inc. (AAPL) returned +110% over 5 years vs BridgeBio Oncology … (BBOT)'s -2%. A $10,000 investment in AAPL 5 years ago would be worth $21,049 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | $0.00 | $0.00 | — |
| Apple Inc. (AAPL) | $215.6B | $416.2B | +93.0% |
Apple Inc.'s revenue grew from $215.6B (2016) to $416.2B (2025) — a 7.6% CAGR.
Chart 3P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Apple Inc. (AAPL) | 18.4 | 36.4 | +97.8% |
Apple Inc. has traded in a 13x–41x P/E range over 9 years; current trailing P/E is ~35x.
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | -0 | 0.46 | +22004.8% |
| Apple Inc. (AAPL) | 2.08 | 7.46 | +258.7% |
Apple Inc.'s EPS grew from $2.08 (2016) to $7.46 (2025) — a 15% CAGR.
Chart 5Free Cash Flow — 5 Years
BridgeBio Oncology Therapeutics Inc. generated $-1M FCF in 2024. Apple Inc. generated $99B FCF in 2025 (+6% vs 2021).
BBOT vs AAPL: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is BBOT or AAPL a better buy right now?
BridgeBio Oncology Therapeutics Inc. (BBOT) offers the better valuation at 21.8x trailing P/E, making it the more compelling value choice. Analysts rate BridgeBio Oncology Therapeutics Inc. (BBOT) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BBOT or AAPL?
On trailing P/E, BridgeBio Oncology Therapeutics Inc. (BBOT) is the cheapest at 21.8x versus Apple Inc. at 35.4x.
03Which is the better long-term investment — BBOT or AAPL?
Over the past 5 years, Apple Inc. (AAPL) delivered a total return of +110.5%, compared to -1.6% for BridgeBio Oncology Therapeutics Inc. (BBOT). A $10,000 investment in AAPL five years ago would be worth approximately $21K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AAPL returned +1027% versus BBOT's -1.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BBOT or AAPL?
By beta (market sensitivity over 5 years), BridgeBio Oncology Therapeutics Inc. (BBOT) is the lower-risk stock at 0.26β versus Apple Inc.'s 1.28β — meaning AAPL is approximately 400% more volatile than BBOT relative to the S&P 500.
05Which has better profit margins — BBOT or AAPL?
Apple Inc. (AAPL) is the more profitable company, earning 26.9% net margin versus 0.0% for BridgeBio Oncology Therapeutics Inc. — meaning it keeps 26.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AAPL leads at 32.0% versus 0.0% for BBOT. At the gross margin level — before operating expenses — AAPL leads at 46.9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is BBOT or AAPL more undervalued right now?
Analyst consensus price targets imply the most upside for BBOT: 132.6% to $23.33.
07Which pays a better dividend — BBOT or AAPL?
In this comparison, AAPL (0.4% yield) pays a dividend. BBOT does not pay a meaningful dividend and should not be held primarily for income.
08Is BBOT or AAPL better for a retirement portfolio?
For long-horizon retirement investors, BridgeBio Oncology Therapeutics Inc. (BBOT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.26)). Both have compounded well over 10 years (BBOT: -1.6%, AAPL: +1027%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between BBOT and AAPL?
These companies operate in different sectors (BBOT (Healthcare) and AAPL (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.